Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Durable responses in metastatic cancers have been achieved with a variety of immunotherapies such as interleukin-2, adoptive cell transfer of tumor-infiltrating lymphocytes, antibodies that block cytotoxic T-lymphocyte–associated antigen 4 (CTLA4),1-5 and antibodies that block programmed death 1 (PD-1).6-10 However, in a recent study, approximately 25% of patients with melanoma who had had an objective response […]

Cervical Carcinoma

Worldwide, cervical carcinoma is the second most common female malignancy, causing approximately 500,000 new cases each year.1 It is responsible for 274,000 deaths and is the third most common cause of female mortality. In Europe the crude mortality rate is 5.9/100,000 women/year but the mortality rate is 10 times higher in developing countries. It has […]

Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance.

  Glucocorticoids are important hormones in the regulation of metabolic homeostasis. We infused normal ratswith dexamethasone given intracerebroventricularly (i.c.v.) for 3 days. This resulted in hyperphagia,hyperinsulinemia, and marked insulin resistance. Similar metabolic defects were observed following i.c.v. infusion of neuropeptide Y (NPY) in normal rats. As central dexamethasone infusion enhanced NPY content in the arcuate […]

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Women with early-stage breast cancer are often treated with adjuvant systemic therapy consisting of chemotherapy, endocrine therapy, agents against human epidermal growth factor receptor 2 (HER2), or combinations of these drugs when appropriate. Treatment decisions are based on characteristics of the tumor (hormonal receptor and HER2 status, tumor grade and size, and lymph-node status) and […]

Skip to toolbar